HC Wainwright Reiterates “Buy” Rating for BioCardia (NASDAQ:BCDA)

BioCardia (NASDAQ:BCDAGet Free Report)‘s stock had its “buy” rating reissued by analysts at HC Wainwright in a research note issued to investors on Wednesday, Benzinga reports. They currently have a $60.00 price objective on the stock.

BioCardia Stock Performance

Shares of NASDAQ BCDA opened at $5.20 on Wednesday. The company has a market capitalization of $141.98 million, a P/E ratio of -11.06 and a beta of 1.47. BioCardia has a 52-week low of $4.51 and a 52-week high of $43.80. The company’s 50 day moving average price is $5.72 and its 200-day moving average price is $7.41.

BioCardia (NASDAQ:BCDAGet Free Report) last released its quarterly earnings data on Tuesday, May 14th. The company reported ($1.35) earnings per share for the quarter. The company had revenue of $0.06 million during the quarter. BioCardia had a negative net margin of 2,208.76% and a negative return on equity of 3,638.68%. During the same period in the prior year, the company earned ($2.55) EPS. Analysts forecast that BioCardia will post -0.42 earnings per share for the current year.

About BioCardia

(Get Free Report)

BioCardia, Inc, a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases in the United States. Its leading product candidate is CardiAMP, an autologous mononuclear cell therapy system in Phase III clinical trial for the treatment of ischemic heart failure with reduced ejection fraction and refractory angina resulting from chronic myocardial ischemia.

Featured Stories

Receive News & Ratings for BioCardia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioCardia and related companies with MarketBeat.com's FREE daily email newsletter.